About this trial
The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.
Eligibility criteria
Qualifiers
abnormal uterine NK cell function;
have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;
have clear fertility desires;
normal ovarian function or with frozen embryos;
Disqualifiers
using progesterone receptor modulator;
chromosomal karyotype abnormalities in one spouse;
severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;
uncontrolled autoimmune diseases;
Trial design
Treatments tested in this trial
- autologous decidual-like NK cells
Treatment groups
Sponsors and collaborators
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead sponsor
The University of Science and Technology of China
Collaborator